Knight Therapeutics Inc. (GUD : TSX)
Common Stock
$9.23
CAD
-0.08 (-0.86%)
Last updated: 2026-06-23
GUD
Knight Therapeutics Inc.
WealthAwesomePerformance
1 Day
-0.86%
1 Week
-0.65%
1 Month
+10.54%
YTD
+56.18%
Key Statistics
Market Cap
$914.05M
52W High
$9.59
52W Low
$5.66
P/E Ratio
155.17
50 Day MA
$8.27
200 Day MA
$6.69
Beta
0.07
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/23/2026 | $9.30 | $9.34 | $9.00 | $9.23 | $9.23 | 44,070 |
| 6/22/2026 | $9.46 | $9.46 | $9.28 | $9.31 | $9.31 | 69,997 |
| 6/19/2026 | $9.02 | $9.38 | $9.02 | $9.27 | $9.27 | 37,943 |
| 6/18/2026 | $9.32 | $9.47 | $9.27 | $9.32 | $9.32 | 112,204 |
| 6/17/2026 | $9.29 | $9.36 | $9.24 | $9.31 | $9.31 | 60,673 |
| 6/16/2026 | $9.49 | $9.49 | $9.25 | $9.29 | $9.29 | 56,897 |
| 6/15/2026 | $9.48 | $9.55 | $9.42 | $9.48 | $9.48 | 72,054 |
| 6/12/2026 | $9.40 | $9.59 | $9.30 | $9.48 | $9.48 | 81,074 |
| 6/11/2026 | $9.34 | $9.44 | $9.25 | $9.38 | $9.38 | 126,884 |
| 6/10/2026 | $9.15 | $9.38 | $9.15 | $9.33 | $9.33 | 172,340 |
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 6.5% over the next 12 months.
Consensus
No RatingAvg. Target
C$9.83
+6.5% Upside
Current Price
C$9.23
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
28.0%
Annualized
90-Day Vol
31.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.03
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$9.80 | C$8.89 โ C$10.79 |
| 60 trading days | C$10.40 | C$9.07 โ C$11.92 |
| 90 trading days | C$11.03 | C$9.33 โ C$13.04 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Knight Therapeutics Inc.
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
Financials
- Revenue (TTM)
- $510.45M
- EBITDA
- $70.12M
- Profit Margin
- 1.10%
- ROE (TTM)
- 0.71%
- EPS (Diluted)
- 0.06
- Book Value
- 8.01
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About GUD
Articles Featuring GUD.TO
Latest articles and analysis covering GUD.TO
Why Knight Therapeutics Inc. stock is gaining today
Knight Therapeutics Inc. has gained 1.30% today, closing at CA$9.35, following the announcement of the repayment of its revolving credit facility, indicating strong cash flow and a positive outlook for future growth.
Why Knight Therapeutics Inc. stock is skyrocketing today
Knight Therapeutics Inc. (GUD.TO) has seen a notable increase of 6.16% in its stock price today, driven by strategic corporate developments that have piqued investor interest.
Why Knight Therapeutics Inc. stock is skyrocketing today
Knight Therapeutics Inc. has surged 6.04% today, closing at CA$9.13, driven by positive market sentiment and strategic announcements. Investors should weigh the potential for growth against the high valuation metrics.
